Sirona Biochem Announces Preclinical Results of Diabetes Compound
News Feb 28, 2012
Sirona Biochem Corp. has announced that its lead compound for the treatment of Type 2 diabetes was effective in lowering blood glucose levels in a well-established preclinical diabetic model.
Sirona Biochem's compound, SBM-TFC-039, significantly and rapidly reduced the blood glucose level in obese diabetic rats (Zucker).
In an acute dosing study, six hours after treatment, the blood glucose level of obese diabetic rats was reduced to the level of control lean rats.
There was a strong correlation between the decrease in blood glucose level (0 to 6 hours post treatment) and the excretion of urinary glucose.
A study in normal rats also confirmed that SBM-TFC-039 triggered elimination of glucose through the urine (glycosuria) in a dose dependent manner.
SBM-TFC-039 also reduced blood glucose excursions following a glucose challenge by 34 percent compared to an untreated group. A separate safety study of SBM-TFC-039 showed the compound was well-tolerated.
SBM-TFC-039 is a sodium glucose transporter (SGLT) inhibitor. SGLT inhibitors are a new class of drug candidates for diabetes.
In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
In addition to the SGLT inhibitor program, Sirona Biochem is continuing progress of its studies of skin lighteners and anti-aging agents for cosmetic use, inducers for recombinant protein production and adjuvants for cell and organ preservation.
All of the programs leverage the company's proprietary chemistry technology.
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Radioprotective Drugs Assessed Using Human Gut Organ-on-a-ChipNews
Researchers have published a study using an organ-on-a-chip (Organ Chip) model of the human gut that reveals the intestinal blood vessel cells may play an important part in radiation-induced intestinal injury, and it confirms that a potential radioprotective drug, dimethyloxaloylglycine (DMOG), suppresses the intestine’s responses to radiation injury.READ MORE
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE